P2X3 receptor antagonism attenuates the progression of heart failure

Autor: Renata M. Lataro, Davi J. A. Moraes, Fabio N. Gava, Ana C. M. Omoto, Carlos A. A. Silva, Fernanda Brognara, Lais Alflen, Vânia Brazão, Rafaela Pravato Colato, José Clóvis do Prado, Anthony P. Ford, Helio C. Salgado, Julian F. R. Paton

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)

Despite medications, heart failure worsens with time with many patients dying within five years of diagnosis. Here the authors show that blocking purinergic receptors in the carotid body stops heart failure progression, improves its function, reduces

Externí odkaz: https://doaj.org/article/e48a184e40354b858155e387d19d724e

Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial

Autor: Fernando J, Martinez, Amna Sadaf, Afzal, Jaclyn A, Smith, Anthony P, Ford, Jerry Jing, Li, Yuping, Li, Michael M, Kitt, Murali, Ramaswamy

Publikováno v: Pulmonary Therapy
Chronic Cough in IPF Study Group, Martinez, F J, Afzal, A S, Smith, J A, Ford, A P, Li, J J, Li, Y & Kitt, M M 2021, ' Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial ', Pulmonary therapy . https://doi.org/10.1007/s41030-021-00162-9

Introduction Chronic cough is a highly problematic symptom for patients with idiopathic pulmonary fibrosis (IPF); limited therapeutic options are available. We evaluated gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough in IP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d58682a6e9f33e7a4abb1f43461f81e0
https://doi.org/10.1007/s41030-021-00162-9

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

Autor: Lorcan P McGarvey, Zhi Jin Xu, Vivek Iyer, James Krainson, James H. Hull, Mark H Gotfried, Jaclyn A Smith, David Muccino, Gary C Steven, Douglas McQuaid, David I. Bernstein, Gregory Daniel Brooks, David Elkayam, Wen-Chi Wu, Selwyn Spangenthal, Mandel R Sher, Jaclyn A. Smith, Yu-Ping Li, John J Condemi, Ellen R Sher, John R Holcomb, W. Carr, Gary N Gross, SM Parker, Gary D Berman, Ratko Djukanovic, Thomas B. Casale, Jason H Friesen, Krishna Sundar, Christopher E. Brightling, Michael Denenberg, Neil Ettinger, S S Birring, Faisal Alfonso Fakih, Bruce M Prenner, Lorcan McGarvey, Niran J Amar, Jonathan Corren, Tim Harrison, Shaila U Gogate, William W. Storms, Alyn H. Morice, Iftikhar Hussain, Leon S Greos, Anthony Montanaro, Anthony P. Ford, James S Good, Eric J Schenkel, Surinder S. Birring, Thomas R Murphy, Michael S Kaplan, William R Lumry, Jonathan Matz, Michael M. Kitt, Mandel Sher, Alan B Goldsobel, Ian D. Pavord

Publikováno v: Protocol 012 Investigators 2020, ' Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(19)30471-0

BACKGROUND: Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed8062bd34a8ad548083ad97ee59fbd
https://pure.qub.ac.uk/en/publications/gefapixant-a-p2x3-receptor-antagonist-for-the-treatment-of-refractory-or-unexplained-chronic-cough-a-randomised-doubleblind-controlled-parallelgroup-phase-2b-trial(5aa94b05-a819-433a-a265-b0ce6c143476).html

Action of MK‐7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation

Autor: David Richards, Anthony P. Ford, Joel R. Gever, Samuel J. Fountain

Publikováno v: Br J Pharmacol

Background & Purpose The P2X3 receptor is an ATP‐gated ion channel expressed by sensory afferent neurons, and is as a target to treat chronic sensitisation conditions. The first‐in‐class, selective P2X3 and P2X2/3 receptor antagonist, the diami

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6a7c5826fa0308e02438d2bc283b8e8
https://doi.org/10.1111/bph.14677

Site Discrimination and Anisotropic Growth Inhibition by Molecular Imposters on Highly Dissymmetric Crystal Surfaces

Autor: Laura N. Poloni, Michael D. Ward, Anthony P. Ford

Publikováno v: Crystal Growth & Design. 16:5525-5541

Drug-induced calculi account for 1–2% of all renal calculi, posing a threat to human health and hindering the development of effective therapies, particularly those based on drug compounds with low solubility. Recently reported compounds from a scr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8144b7cced3c51ff4edd298052a8a36e
https://doi.org/10.1021/acs.cgd.6b01013